Syncell’s Microscoop Winner of BioTech Breakthrough Award For “Proteomics Solution of the Year”
November 21, 2024 20:16 ET
|
BioTech Breakthrough
TAIPEI, Taiwan and WATERTOWN, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Syncell, a leader in next-generation subcellular protein purification and spatial proteomics analysis, today announced that...
Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
November 21, 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
Advanced At-home Biomarker Testing Market USD 2,255.7 Million Growth Forecast Period 2024 to 2034 Comprehensive Analysis and Growth Forecast at a CAGR of 7.5% | FMI
November 15, 2024 08:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Nov. 15, 2024 (GLOBE NEWSWIRE) -- The Advanced At-home Biomarker Testing Market is experiencing a significant growth surge due to the increased adoption of remote health management...
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 08, 2024 10:05 ET
|
Compass Therapeutics
New data showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and disease control in patients treated with CTX-471 monotherapy.Predictive...
Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024
October 24, 2024 08:30 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) and...
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
October 23, 2024 09:15 ET
|
Cyclacel
NEW CLINICAL DATA FROM ONGOING, PHASE 2 STUDY OF ORAL FADRACICLIB AT THE 2024 ENA SYMPOSIUM.
Patients preselected for CDKN2A and/or CDKN2B abnormalities
Preterm Birth and PROM Testing Market Expected to Grow at 8.6% CAGR, projected to Reach USD 562.1 million by 2034 | States Transparency Market Research, Inc.
October 16, 2024 08:59 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Oct. 16, 2024 (GLOBE NEWSWIRE) -- The preterm birth and PROM testing market (早産およびPROM検査市場) was worth US$ 227.8 million in...
RTI International and Codetta Bio™ announce strategic collaboration to accelerate healthcare innovation
October 15, 2024 09:01 ET
|
Codetta Bio, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2024 (GLOBE NEWSWIRE) -- RTI International, a nonprofit research organization, and Codetta Bio™, an emerging leader in multi-omics for precision medicine, are...
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
October 09, 2024 09:15 ET
|
Cyclacel
Initial safety and efficacy data from fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
September 25, 2024 09:15 ET
|
Cyclacel
Cyclacel announces completion of enrollment in the biomarker-enriched
cohort of its Phase 2 study
- Patients are preselected for C